Idaho Healthcare Hub: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Idaho Healthcare Hub.

Press releases published on April 23, 2026

Apr. 23, 2026

Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms

Indeterminate GlobeNewswire

Apr. 23, 2026

ENA Respiratory Appoints Melissa Faris to Board

Indeterminate GlobeNewswire

Apr. 23, 2026

Epitopea annonce l'approbation de la demande d'essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l'ovaire séreux de haut grade avancé

Indeterminate GlobeNewswire

Apr. 23, 2026

Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)

Indeterminate GlobeNewswire

Apr. 23, 2026

Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours

Indeterminate GlobeNewswire

Apr. 23, 2026

Orion Pharma on aloittanut TEADCO Faasi 1b/2 -tutkimuksen ODM-212-molekyylillä yhdessä vakiintuneiden hoitojen kanssa potilailla, joilla on tiettyjä pitkälle edenneitä kiinteitä kasvaimia

Indeterminate GlobeNewswire

Apr. 23, 2026

OSE Immunotherapeutics annonce la présentation des résultats de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire au Congrès 2026 de l’ASCO

Indeterminate GlobeNewswire

Apr. 23, 2026

Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA

Indeterminate GlobeNewswire

Apr. 23, 2026

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting

Indeterminate GlobeNewswire

Apr. 23, 2026

Press Release: Q1 2026: double-digit sales and business EPS growth

Indeterminate GlobeNewswire

Apr. 23, 2026

Santhera ernennt Orlando Oliveira zum Chief Executive Officer

Indeterminate GlobeNewswire

Apr. 23, 2026

Santhera Appoints Orlando Oliveira as Chief Executive Officer

Indeterminate GlobeNewswire

Apr. 23, 2026

Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance

Indeterminate GlobeNewswire

Apr. 23, 2026

Ipsen enregistre une forte croissance de ses ventes au premier trimestre 2026 et confirme ses objectifs annuels

Indeterminate GlobeNewswire

Apr. 23, 2026

Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Indeterminate GlobeNewswire

Apr. 23, 2026

Nobelpreisverdächtige Entdeckung von VectorBuilder-Wissenschaftlern deckt grundlegende Entwicklungsmechanismen auf

Indeterminate GlobeNewswire

Apr. 23, 2026

Une découverte susceptible de valoir un prix Nobel par les scientifiques de VectorBuilder révèle les mécanismes fondamentaux du développement

Indeterminate GlobeNewswire

Apr. 23, 2026

New funding opportunities pave the way for better diagnostics and treatment as well as for engineering efficient biosolutions and replacing critical and scarce resources

Indeterminate GlobeNewswire

Apr. 23, 2026

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Indeterminate GlobeNewswire